title: Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.
abstract: Imaging biomarkers are useful outcome measures in treatment trials. We compared sample size estimates for future treatment trials performed over 6 or 12-months in progressive supranuclear palsy using both imaging and clinical measures. We recruited 16 probable progressive supranuclear palsy patients that underwent baseline, 6 and 12-month brain scans, and 16 age-matched controls with serial scans. Disease severity was measured at each time-point using the progressive supranuclear palsy rating scale. Rates of ventricular expansion and rates of atrophy of the whole brain, superior frontal lobe, thalamus, caudate and midbrain were calculated. Rates of atrophy and clinical decline were used to calculate sample sizes required to power placebo-controlled treatment trials over 6 and 12-months. Rates of whole brain, thalamus and midbrain atrophy, and ventricular expansion, were increased over 6 and 12-months in progressive supranuclear palsy compared to controls. The progressive supranuclear palsy rating scale increased by 9 points over 6-months, and 18 points over 12-months. The smallest sample size estimates for treatment trials over 6-months were achieved using rate of midbrain atrophy, followed by rate of whole brain atrophy and ventricular expansion. Sample size estimates were further reduced over 12-month intervals. Sample size estimates for the progressive supranuclear palsy rating scale were worse than imaging measures over 6-months, but comparable over 12-months. Atrophy and clinical decline can be detected over 6-months in progressive supranuclear palsy. Sample size estimates suggest that treatment trials could be performed over this interval, with rate of midbrain atrophy providing the best outcome measure.
authors.affiliation: Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Whitwell.jennifer@mayo.edu
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Whitwell
authors.forename: Jia
authors.initials: J
authors.lastname: Xu
authors.forename: Jay N
authors.initials: JN
authors.lastname: Mandrekar
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Gunter
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Jack
authors.forename: Keith A
authors.initials: KA
authors.lastname: Josephs
mesh_terms: D000328:Adult; D000368:Aged; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018401:Sample Size; D013494:Supranuclear Palsy, Progressive / Q000473:pathology*
references.citation: J Neurol. 2007 Apr;254(4):478-81
references.pmid: 17401522
references.citation: Brain. 2006 Apr;129(Pt 4):1040-9
references.pmid: 16455792
references.citation: Radiology. 2008 Jan;246(1):214-21
references.pmid: 17991785
references.citation: Neuroimage. 2006 Apr 1;30(2):436-43
references.pmid: 16300968
references.citation: IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
references.pmid: 9617910
references.citation: AJNR Am J Neuroradiol. 2001 Sep;22(8):1483-9
references.pmid: 11559495
references.citation: Arch Neurol. 2006 Jan;63(1):81-6
references.pmid: 16401739
references.citation: Arch Neurol. 2009 Feb;66(2):201-7
references.pmid: 19204156
references.citation: Parkinsonism Relat Disord. 2011 Sep;17(8):599-605
references.pmid: 21665514
references.citation: Brain. 2007 Apr;130(Pt 4):1148-58
references.pmid: 17347250
references.citation: Neurology. 2005 Jun 28;64(12):2050-5
references.pmid: 15985570
references.citation: Neuron. 2002 Jan 31;33(3):341-55
references.pmid: 11832223
references.citation: Neuroimage. 1999 Feb;9(2):195-207
references.pmid: 9931269
references.citation: Neurology. 1996 Jul;47(1):1-9
references.pmid: 8710059
references.citation: Brain. 2007 Jun;130(Pt 6):1552-65
references.pmid: 17405767
references.citation: Acta Neurol Scand. 2007 Jul;116(1):37-42
references.pmid: 17587253
references.citation: Ann Neurol. 1999 Jan;45(1):65-74
references.pmid: 9894879
references.citation: AJNR Am J Neuroradiol. 2009 Sep;30(8):1482-7
references.pmid: 19589886
references.citation: Acta Neuropathol. 2011 Aug;122(2):137-53
references.pmid: 21614463
references.citation: Ann Neurol. 2006 Jan;59(1):200-3
references.pmid: 16278856
references.citation: Neuroimage. 2006 Jul 1;31(3):968-80
references.pmid: 16530430
references.citation: IEEE Trans Med Imaging. 1997 Oct;16(5):623-9
references.pmid: 9368118
references.citation: Neurobiol Aging. 2008 Feb;29(2):280-9
references.pmid: 17097770
references.citation: Eur J Neurosci. 2010 Aug;32(4):640-7
references.pmid: 20597976
references.citation: J Magn Reson Imaging. 2003 Jul;18(1):16-24
references.pmid: 12815635
references.citation: Neurology. 2005 Jul 12;65(1):119-24
references.pmid: 16009896
references.citation: J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):457-63
references.pmid: 16306152
references.citation: Parkinsonism Relat Disord. 2011 Mar;17(3):172-6
references.pmid: 21236720
references.citation: Neurology. 1999 Oct 12;53(6):1292-9
references.pmid: 10522887
references.citation: J Neurol. 1999 Sep;246 Suppl 2:II6-15
references.pmid: 10525997